Tag: hormoneRecPositiveArticle

Articles

• Breast cancer types
• ER+/PR+ breast cancer characteristics
• Foods to eat and avoid for ER+/PR+ patients and survivors
• Hormone receptor and HER2 status changes can influence prognosis
• Hormone receptor positive (ER+/PR+) breast cancer prognosis
• Hormone receptor positive (ER+/PR+) recurrence & survival data

Studies

• Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells Cite
  Iriti M, Kubina R, Cochis A, Sorrentino R, Varoni EM, Kabała-Dzik A, et al. Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells. Phytotherapy Research. Wiley; 2017; 31:1529-1538 10.1002/ptr.5878
• β-carotene at physiologically attainable concentration induces apoptosis and down-regulates cell survival and antioxidant markers in human breast cancer (MCF-7) cells Cite
  Sowmya Shree G, Yogendra Prasad K, Arpitha HS, Deepika UR, Nawneet Kumar K, Mondal P, et al. β-carotene at physiologically attainable concentration induces apoptosis and down-regulates cell survival and antioxidant markers in human breast cancer (MCF-7) cells. Molecular and Cellular Biochemistry. Springer Science and Business Media LLC; 2017; 436:1-12 10.1007/s11010-017-3071-4
• Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer Cite
  Devlin KL, Sanford T, Harrison LM, LeBourgeois P, Lashinger LM, Mambo E, et al. Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0159686 10.1371/journal.pone.0159686
• Breast Cancer and Obesity: In Vitro Interferences between Adipokines and Proangiogenic Features and/or Antitumor Therapies? Cite
  Dubois V, Delort L, Billard H, Vasson M, Caldefie-Chezet F. Breast Cancer and Obesity: In Vitro Interferences between Adipokines and Proangiogenic Features and/or Antitumor Therapies?. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e58541 10.1371/journal.pone.0058541
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102